There is new optimism for phage therapy, an approach that has been with us for 100 years and is now being embraced anew. A rigorous clinical and biological approach will serve us well and effective partnerships between government, industry and the academy are essential.
In an ideal world, a phage biobank would be a facility that serves as a primary research and therapeutic development resource for researchers studying critical infection, as well as to the wider community of infectious diseases, industry and biotech with an interest in critical infection.
Winter 2014, I was revising a grant proposal to develop methods for characterizing bacterial methylomes, the collective DNA methylation events beyond the four canonical bases, G, A, T and C.
Behind the Paper: Home chemical and microbial transitions across urbanization